In this multicentre , open-label , phase @b , non-inferiority study , HIV-@-infected antiretroviral therapy-naive adults with HIV-@ RNA concentration of @ copies per mL or more and no resistance at screening were randomly assigned ( @:@ ) to receive either dolutegravir @ mg once daily or darunavir @ mg plus ritonavir @ mg once daily , with investigator-selected tenofovir-emtricitabine or abacavir-lamivudine .